Bio Medica Laboratories Limited
NSE: BMLL · Pharmaceuticals
Share price ₹160.70
up 10.83% · close of 20 Nov 2026
Your ratios
Market cap
₹202 Cr
P/E ratio
17.0
EPS FY to Mar 2026
P/B ratio
Pending
₹47 Cr IPO · by 27 May
ROCE
37.5%
ROE
58.0%
Dividend yield
0.0%
as of 20 Nov 2026
1 · Overview
Overview
Price, valuation, sales and profit over the range you pick. Prices as of the last close; results as filed.
At a glance · Max
Every small chart follows the range above. Point at it to read a value; click it to open it.2 · Results
Latest result · Q2 FY27
What the last results showed. Whether management kept its word is in Pro.
Net profit ₹3.00 Cr in the quarter to Sep 2026
Years to March, 2023–2026 · key lines
| Line | Mar 2023FY23 | Mar 2024FY24 | Mar 2025FY25 | Mar 2026FY26 |
|---|---|---|---|---|
| Sales₹ crore | 16.23 | 15.25change on a year before -6% | 38.00change on a year before +149% | 43.00change on a year before +13% |
| Expenses₹ crore | 23 | 23 | ||
| Operating profit₹ crore | 15 | 20change on a year before +33% | ||
| Operating margin% of sales | 10.47% | 36.93% | 40.00% | 46.00% |
| Interest₹ crore | 1 | 2 | ||
| Depreciation₹ crore | 1 | 1 | ||
| Profit before tax₹ crore | 13 | 16 | ||
| Tax rate% of profit before tax | 25.00% | 27.00% | ||
| Net profit₹ crore | 0.33 | 2.50change on a year before +658% | 10.00change on a year before +300% | 12.00change on a year before +20% |
| EPS₹ per share | 0.36 | 2.72change on a year before +656% | 10.66change on a year before +292% | 12.95change on a year before +21% |
Small figure: change on the year before. Lines that are 0 or blank in every column are not shown.
The last 4 quarters, Mar 2025 to Sep 2026 · key lines
| Line | Mar 2025Q4 FY25 | Sep 2025Q2 FY26 | Mar 2026Q4 FY26 | Sep 2026Q2 FY27 |
|---|---|---|---|---|
| Sales₹ crore | 19.14 | 18.40 | 43.00 | 22.00 |
| Expenses₹ crore | 12.15 | 10.60 | 23.00 | 15.00 |
| Operating profit₹ crore | 6.99 | 7.80 | 20.00 | 6.00 |
| Operating margin% of sales | 36.52% | 42.39% | 46.00% | 28.00% |
| Other income₹ crore | -0.06 | 0.06 | 0.00 | 1.00 |
| Interest₹ crore | 0.73 | 0.60 | 2.00 | 1.00 |
| Depreciation₹ crore | 0.50 | 0.34 | 1.00 | 1.00 |
| Profit before tax₹ crore | 5.70 | 6.92 | 16.00 | 5.00 |
| Tax rate% of profit before tax | 27.54% | 24.71% | 27.00% | 29.00% |
| Net profit₹ crore | 4.13 | 5.21 | 12.00 | 3.00 |
| EPS₹ per share | 4.50 | 5.68 | 13.06 | 2.93 |
Small figure: change on the same quarter a year earlier.
Filed only on the standalone basis, so shown from it: Depreciation, EPS, Expenses, Interest, Net profit, Operating margin, Operating profit, Other income, Profit before tax, Sales, Tax rate.
Sales and profit: growth a year, compounded, to Mar 2026; TTM is the last 12 months. Share price: to the latest close. A span can cross a demerger or an acquisition.
Sales
a year, compounded
- 3 years
- 38%
- TTM
- 12%
Return on equity
average over the span
- Last year
- 58%
3 · Quality & value
Answers
The questions investors ask most, each answered first in one line, then shown. From the company's own numbers.
How fast it has been growing
Fewer than three years of filings — too early to judge growth.
Whether it grew faster than its sector
It grew 38.4% a year against a sector median of 9.8% — 28.6 percentage points faster.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
It has no steady three-year profit record yet, so growth cannot be weighed against the price.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 8 of 132 on returns, 5 of 132 on margin.
A longer bar is a better rank.
What makes it hard to beat — and is that still true?
A wide advantage: it earns 37.5% on capital, ahead of 94% of companies filed under the same label.
Whether its growth pays for itself
Only 2 years of matching accounts on file — too few to judge this yet.
Peers here are the 132 companies the exchange files under the same label (Pharmaceuticals). That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Business score & profit checks
How strong the business is, and whether its profit is real cash. Facts only, not advice.
Business score
53 out of 100
How strong the business is, in one number. Last changed 20 Nov 2026.
Profit checks: is the profit real cash?
5 of 7 checks clear
2 of 9 checks could not be run.
Simple checks on the accounts. Which 2 are flagged is in Pro.
Key numbers & peers
Grouped by topic. Each number says what period it is for.
Price
- Market cap
- ₹202 Cr
- Prev close
- ₹160.70
- 52w High
- ₹181
- 52w Low
- ₹141
- Beta
- —
- Price CAGR 1y
- —
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Valuation
- P/E ratioEPS FY to Mar 2026
- 17.0
- Industry P/E
- 34.7
- P/B ratio₹47 Cr IPO · by 27 May
- Pending
- EV / EBITDA₹47 Cr IPO · by 27 May
- Pending
- Enterprise value₹47 Cr IPO · by 27 May
- Pending
- PEG ratio
- —
- Dividend yield
- 0.0%
Returns
- ROCE
- 37.5%
- ROCE 5y average
- 37.5%
- ROE
- 58.0%
- ROE 3y average
- —
- ROE last year
- 58.0%
- Return on assets
- 16.4%
Sales, profit & margins
- Annual revenue
- ₹43.0 Cr
- Annual profit
- ₹12.0 Cr
- EPS
- ₹13.0
- Operating margin
- 46.0%
- Net profit margin
- 27.9%
- EBITDA margin
- 46.5%
- Sales latest quarterSep 2026 quarter
- ₹22.0 Cr
- Profit latest quarterSep 2026 quarter
- ₹3.00 Cr
- OPM latest quarterSep 2026 quarter
- 28.0%
Growth a year
- Sales growth 3y
- 38.4%
- Sales growth 5y
- —
- Sales growth TTM
- 12.0%
- Profit growth 3y
- —
- Profit growth 5y
- —
- Profit growth TTM
- —
- YoY quarterly sales growth
- —
- YoY quarterly profit growth
- —
Balance sheet
- Book Value
- Pending
- Face Value
- ₹10.0
- Borrowings
- ₹40.0 Cr
- Total debt
- ₹33.0 Cr
- Total cash
- ₹25.1 Cr
- Debt / Equity
- 0.5
- Interest coverage
- 9.0
- Reserves / Equity
- 1.9
Cash & payout
- Operating cash flow
- -₹6.00 Cr
- Free cash flow
- -₹6.00 Cr
- FCF yield
- -4.0%
- Net cash flow
- ₹0.00 Cr
- Dividend payout
- 0.0%
Holdings
- Promoter holding
- 67.7%
- FII holding
- 4.8%
- DII holding
- 3.6%
- Public holding
- 23.9%
A newly listed company shows “Pending” until it files a balance sheet after its IPO: the last one is from before the issue, so the IPO money would be counted twice.
Peers
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield | Profit qtr ₹ Cr | Profit change | Sales qtr ₹ Cr | Sales change | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 1,884.90 | 36.8 | 4,52,244 | 0.86% | 1,995 | -36.16% | 16,199 | +11.88% | 20.60% |
| Divi's Laboratories | 11,180.50 | 86.7 | 2,96,283 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharmaceuticals | 4,689.50 | 81.1 | 1,78,370 | 0.82% | 534 | -9.64% | 4,979 | +50.79% | 19.56% |
| Laurus Labs Limited | 2,294.60 | 92.5 | 1,23,977 | 0.09% | 436 | +124.84% | 2,206 | +33.44% | 17.97% |
| Zydus Lifesciences | 1,200.00 | 26.2 | 1,19,760 | 0.08% | 928 | -25.13% | 7,910 | +29.17% | 22.69% |
| Dr Reddy's Laboratories | 1,390.20 | 41.5 | 1,16,082 | 0.58% | 913 | -31.70% | 8,698 | -1.48% | 13.75% |
| Cipla | 1,415.00 | 36.8 | 1,14,311 | 0.93% | 852 | -37.07% | 7,404 | -2.44% | 16.66% |
| Bio Medica Laboratories Limited | 160.70 | 17.0 | 202 | 0.00% | 3.00 | 22.0 | 37.50% | ||
| Medianof the whole group of 129, 20 Nov 2026 | 34.9 | 0.09% | +33.42% | +19.60% | 15.01% |
Median: the middle value of the whole peer group of 129 companies. Price and rupee sizes are left blank there, as a middle value of those says little.
Competes with 7 listed companies
Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
4 · Balance sheet & cash
Balance sheet
What the company owns and what it owes, at each year end and at the filed half-years. ₹ crore.
At Mar 2026: ₹73.0 cr of assets, and who funds them
Shareholders’ own money funds 36% of it; borrowings 55%.
What it owns
- Fixed assets ₹17.0 cr 23%
- Everything else ₹56.0 cr 77%
Who funds it
- Shareholders’ money ₹26.0 cr 36%
- Borrowings ₹40.0 cr 55%
- Everything else ₹7.00 cr 10%
Each year end. Newest year end shaded.
| Line, ₹ crore | Mar 2025FY25 | Mar 2026FY26 |
|---|---|---|
| Equity capital | 9 | 9 |
| Reserves | 6 | 17 |
| Borrowings | 15 | 40 |
| Other liabilities | 9 | 7 |
| Total funding | 39 | 73 |
| Fixed assets | 8 | 17 |
| Other assetsreceivables, cash, rest | 31 | 56 |
| Total assets | 39 | 73 |
Cash flows
Real money coming in and going out — from the business, from investments and from loans. ₹ crore.
Pick a period to see where its cash went.
In words
- The business used ₹6.00 cr more than it brought in.
- It put ₹2.00 cr into assets and investments.
- It raised ₹8.00 cr from shareholders and lenders.
- Cash in hand rose by ₹0.00 cr. Free cash flow: −₹6.00 cr.
| Line, ₹ crore | Mar 2025FY25 | Mar 2026FY26 |
|---|---|---|
| From the business | -5 | -6 |
| From investing | 0 | -2 |
| From financingdividends, buybacks, loans | 5 | 8 |
| Free cash flow | -5 | -6 |
| Cash ÷ operating profitbefore tax | -33.00% | -30.00% |
Free cash flow = cash from the business − spending on assets + what assets sold fetched; the same rule for years and half-years.
Efficiency ratios
How fast customers pay and how well capital earns. Each year, Mar 2025 to Mar 2026.
Debtor days
92 days
Days customers take to pay. Lower is faster.
92 days in FY26, against 39 days in FY25. Over these 2 years: 39 days (FY25) to 92 days (FY26).
Inventory days
1338 days
Days stock sits before it is sold.
1338 days in FY26, against 678 days in FY25. Over these 2 years: 678 days (FY25) to 1338 days (FY26).
Days payable
205 days
Days it takes to pay its suppliers.
205 days in FY26, against 160 days in FY25. Over these 2 years: 160 days (FY25) to 205 days (FY26).
Cash conversion cycle
1225 days
Debtor days plus inventory days, less days payable.
1225 days in FY26, against 557 days in FY25. Over these 2 years: 557 days (FY25) to 1225 days (FY26).
Working capital days
300 days
Days of sales tied up in running the business.
300 days in FY26, against 166 days in FY25. Over these 2 years: 166 days (FY25) to 300 days (FY26).
5 · Owners & payouts
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividend a share, by the year of its ex-date
No dividend on record.
Share of profit paid as dividend
No dividend payout is filed for this company.
Splits, bonuses & buybacks
None on record.
Big trades by funds and insiders
- JAYANT BABULAL BOKADIAbulk deal, NSESold 80,000 · at ₹146.0027 Oct 2026
- OSWAL ENERGIES LIMITEDbulk deal, NSEBought 80,000 · at ₹146.0027 Oct 2026
- OSWAL ENERGIES LIMITEDbulk deal, NSEBought 1,44,000 · at ₹146.0026 Oct 2026
- DIXIT JITENDRA BOKADIAbulk deal, NSESold 75,000 · at ₹146.0026 Oct 2026
- RATAN BABULAL BOKADIAbulk deal, NSESold 69,000 · at ₹146.0026 Oct 2026
- MAHABIR TRADEVENTURES LLPbulk deal, NSESold 1,18,000 · at ₹159.6019 Aug 2026
- AGGARWAL ATUL KASTURILALbulk deal, NSEBought 1,16,000 · at ₹153.5018 Aug 2026
- MAHABIR TRADEVENTURES LLPbulk deal, NSESold 1,16,000 · at ₹153.5018 Aug 2026
- RATHOD MANOJ CHHAGANLAL HUFbulk deal, NSESold 91,000 · at ₹156.3618 Aug 2026
- RATHOD MANOJ CHHAGANLAL HUFbulk deal, NSEBought 46,000 · at ₹156.3718 Aug 2026
The newest 10 of 40 on record.
6 · Price & trading
Open interestPRO
Where option traders are positioned on this stock.
7 · Business
About
What the company is, from our own records: where it sits, where its revenue comes from, and where it works.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Symbol
- BMLL
- ISIN
- INE1BKA01015
- Part of
- Nifty SME Emerge
Sites · 2
- Unit No.1Indore, Madhya Pradesh
- Unit No.2 (Registered Office)Indore, Madhya Pradesh
Industry numbers
The numbers that matter most in this industry, from the company's own filings and earnings calls. Each one says its period.
Revenue and margin
- EBIT marginSep 2026 quarter22.73%
Profit quality
- Other income shareSep 2026 quarter20.00%
- Interest coverMar 2026 quarter9.00x
Capex
- CapexFY to Mar 2026₹0.00 Cr
- Capex to revenueFY to Mar 20260.00%
How they have moved
EBIT margin · quarterly
Source: Computed from the filings
| Sep 26 | 22.73% | Computed from the filings |
| Jun 26 | — | not filed |
| Mar 26 | 44.19% | Computed from the filings |
Other income share · quarterly
Source: Computed from the filings
| Sep 26 | 20.00% | Computed from the filings |
| Jun 26 | — | not filed |
| Mar 26 | 0.00% | Computed from the filings |
Capex (fiscal year) · yearly
Source: Computed from the filings
| FY26 | ₹0.00 Cr | Computed from the filings |
| FY25 | ₹0.00 Cr | Computed from the filings |
Capex to revenue (fiscal year) · yearly
Source: Computed from the filings
| FY26 | 0.00% | Computed from the filings |
| FY25 | 0.00% | Computed from the filings |
Supply chain
Links to other companies, as recorded in our map from filings and announcements. A news event that hits one of them can reach Bio Medica Laboratories Limited through this map.
Exports to · 1
- Afghanistan
Competes with · 7 companies
- Sun Pharmaceutical
- Divi's Laboratories
- Torrent Pharmaceuticals
- Laurus Labs
- Zydus Lifesciences
- Dr Reddy's Laboratories
- Cipla
Shaded: the companies compared in Key numbers & peers. Each name opens that company’s page.
8 · News & documents
News and what it reaches
Filings and news about Bio Medica Laboratories Limited, and bigger events that reach it through its owners, rivals, customers or suppliers. Newest first. Open one to see how the effect spreads.
No recent news or filings for this company.
Documents
Earnings calls, results presentations and annual reports, straight from the company and the exchanges.
No documents on record yet.
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.